New scan could catch breast cancer spread that standard tests miss

NCT ID NCT07313033

Not yet recruiting Diagnosis Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of PET scan using a tracer called 68Ga-FAPI-46 to find cancer that has spread in patients with lobular breast cancer. Standard scans often miss these metastases. The trial will enroll 45 adults whose standard PET scan was negative or unclear, and see if the new scan can spot hidden lesions confirmed by biopsy. If it works, it could lead to better treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-FAPI-46 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could provide a more accurate way to detect breast cancer spread, helping patients avoid undertreatment.
What could go wrong: This is a very early, small study (45 people) with no results yet. The new scan may not find more lesions than the standard scan, and false positives are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Carcinoma, Lobular invasive lobular breast carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER LOBULAR CARCINOMA

Contacts and locations

Locations

Lyon sud Hospital center - Hospices Civils de Lyon

Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.